H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on JSPR stock, giving a Buy rating yesterday.
Emily Bodnar’s rating is based on the promising data from Jasper Therapeutics’ BEACON trial, which evaluated the efficacy of briquilimab in treating chronic spontaneous urticaria (CSU). The trial results showed sustained improvements in UAS7 scores, indicating effective disease control with no new safety concerns emerging over the study period. The data demonstrated that briquilimab maintained its efficacy over time, with significant reductions in UAS7 scores compared to baseline, particularly in certain dosing regimens.
Additionally, the safety profile of briquilimab remained favorable, with low rates of adverse events, which supports its potential as a viable treatment option. The anticipation of further data in mid-2025 from ongoing studies is expected to provide additional support for the drug’s efficacy and safety, reinforcing the decision to maintain a Buy rating. These factors collectively contribute to the positive outlook on Jasper Therapeutics’ stock.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $80.00 price target.